IPSC
Century Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$1.86
−1.06%Price chart
Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18
Key dataSep 18, 2026
Open$1.87
From 52W high−36.73%
Volume1.37M
Market cap$336.80M
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataSep 18, 2026
Open
$1.87
From 52W high
−36.73%
Volume
1.37M
Market cap
$336.80M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−2.6x
P/E (TTM)
—
RSI (14)
37.0
MomentumView details →
1D Return
−1.06%
YTD Return
+83.47%
SummaryUpdated Jun 1, 2026
Century Therapeutics, Inc. (NASDAQ:IPSC) is a biotechnology company founded in 2018 and headquartered in Philadelphia, Pennsylvania. The company went public in June 2021 and focuses on developing innovative cancer treatments using induced pluripotent stem cell (iPSC) technology. Century Therapeutics represents a next-generation approach to cell therapy, aiming to create "off-the-shelf" treatments that could potentially overcome the limitations of traditional personalized cell therapies.
Similar companies
Latest newsMore news →
Douglas Carr, Senior Vice President of Finance & Operations at Century Therapeutics, sold 1,658 shares of the company's common stock on September 14, 2026, at $1.93 per share for a total of $3,199 to cover tax withholding obligations tied to vesting restricted stock units.5d agoCentury Therapeutics, Inc. appointed Joseph Truitt as a member of its Board of Directors, effective September 9, 2026, and granted him an initial option award to purchase 148,000 shares of the company's common stock.11d ago